Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo by Farideh Miraki-Moud, Essam.

Slides:



Advertisements
Similar presentations
Livin in Prognosis of Childhood ALL Livin- member of inhibitor of apoptosis proteins (IAP). – IAP- acts on effector and initiator caspases Function of.
Advertisements

Volume 81, Issue 11, Pages (June 2012)
Molecular Therapy - Nucleic Acids
by Ayten Kandilci, and Gerard C. Grosveld
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples by Keiki Kumano, Shunya Arai, Masataka Hosoi, Kazuki.
MiR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221 by Ai Kotani, Daon.
How I treat LGL leukemia
Identification of key regulatory pathways of myeloid differentiation using an mESC-based karyotypically normal cell model by Dong Li, Hong Yang, Hong Nan,
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells by Jordy Leung, Annie Pang, Wai-Hung Yuen, Yok-Lam.
by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W
Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.
Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis in Peripheral Blood Mononuclear Cell Compartments and Leukemia Cells, While Hematopoetic Stem Cells.
by Koji Yamamoto, Vivian de Waard, Colleen Fearns, and David J
Long-term imatinib therapy promotes bone formation in CML patients
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.
Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias by Masaharu Nakayama, Morimasa.
Volume 67, Issue 5, Pages (May 2005)
Volume 81, Issue 11, Pages (June 2012)
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)‏
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment by Francis Mussai, Carmela De Santo, Issa Abu-Dayyeh, Sarah Booth,
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response by Andreas Rosenwald, Eric Y. Chuang,
by Alexis S. Bailey, Shuguang Jiang, Michael Afentoulis, Christina I
Repression of BMI1 in normal and leukemic human CD34+ cells impairs self-renewal and induces apoptosis by Aleksandra Rizo, Sandra Olthof, Lina Han, Edo.
by Jordi Xaus, Mònica Comalada, Annabel F
Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid–mediated transactivation is dispensable by Scott C. Kogan, Suk-hyun.
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia by Xue-Fei Huang, Shao-Kai Luo,
Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression  Markus D. Herrmann, Jochen.
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia by Rongzhen Xu, Yingzi Yu, Shu Zheng, Xiaoying Zhao,
Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation by Kellie R. Machlus, Stephen K. Wu,
Dual nature of T cell–epithelium interaction in chronic rhinosinusitis
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells by Tomohiko Tamura, Hee Jeong Kong, Chainarong Tunyaplin,
Pegylated arginase I: a potential therapeutic approach in T-ALL
by Xiaowu Zhang, and Ruibao Ren
Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and.
Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From Bone Marrow Macrophages by Sophia.
Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cδ–dependent mechanisms by Man-Gen.
by Susana Constantino Rosa Santos, and Sérgio Dias
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic.
by Anupama Narla, Shilpee Dutt, J
Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro by José Perdomo, Feng Yan,
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma by Vicente Fresquet, Melissa Rieger, Carlo Carolis,
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma by Thorsten Stühmer, Manik Chatterjee, Martin Hildebrandt, Pia.
by Hyung-Gyoon Kim, Kyoko Kojima, C. Scott Swindle, Claudiu V
by Jun Yuan, David B. Lovejoy, and Des R. Richardson
Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells by Simon T. Abrams, Benjamin R. B. Brown,
Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids.
Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,
The BH3-mimetic GX synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak by Patricia Pérez-Galán, Gaël.
Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced.
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells by Bing Z. Carter, Marcela Gronda,
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Zachary A. Hing, Rose Mantel,
Volume 25, Issue 3, Pages (March 2017)
Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute.
Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.
Volume 7, Issue 6, Pages (December 2010)
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,
by Hairui Su, Chiao-Wang Sun, Szu-Mam Liu, Xin He, Hao Hu, Kevin M
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.
VAY-736 combines effectively with ibrutinib in vivo.
SHIP is required for a functional hematopoietic stem cell niche
Volume 83, Issue 3, Pages (March 2013)
Myeloma cell–derived Runx2 promotes myeloma progression in bone
Volume 17, Issue 2, Pages (February 2009)
A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion by Christopher A. Miller, Christopher.
by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E
Volume 13, Issue 1, Pages (January 2006)
Molecular Therapy - Nucleic Acids
ABT-199 efficiently kills primary AML myeloblasts as a single agent.
Volume 21, Issue 4, Pages (April 2013)
SY-1425 induces maturation in RARA-high AML
Presentation transcript:

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo by Farideh Miraki-Moud, Essam Ghazaly, Linda Ariza-McNaughton, Katharine A. Hodby, Andrew Clear, Fernando Anjos-Afonso, Konstantinos Liapis, Marianne Grantham, Fareeda Sohrabi, Jamie Cavenagh, John S. Bomalaski, John G. Gribben, Peter W. Szlosarek, Dominique Bonnet, and David C. Taussig Blood Volume 125(26):4060-4068 June 25, 2015 ©2015 by American Society of Hematology

ASS1 is not expressed in most AML ASS1 is not expressed in most AML. (A) The 2 enzymes required for endogenous arginine synthesis are shown together with the products of arginine following ADI-PEG 20 therapy. ASS1 is not expressed in most AML. (A) The 2 enzymes required for endogenous arginine synthesis are shown together with the products of arginine following ADI-PEG 20 therapy. (B) ASS1 expression was assessed in bone marrow using immunohistochemistry: positive control, liver (top left); control bone marrow (top right). The rest of the panels are pictures of trephines with the diagnosis indicated on each panel. The 2 AML samples are negative (middle right, sample T19; middle left, sample T22), whereas the 2 APL samples express ASS1 (bottom right, sample T3; bottom left, sample T2). Slides were analyzed using a Leica DM2500 microscope with ×100 magnification, and images were acquired by a Leica DFC320 camera and processed using Leica IM50 software. (C) The expression of ASS1 and ASL in primary AML lysates was tested using western blotting. Results for 7 AML, 1 APL, and 1 granulocyte–colony-stimulating factor mobilized peripheral blood (GMPB) samples are shown. (D) The relative expression of ASS1 was quantified by real-time PCR in 4 APL, 38 AML, and 11 GMPB samples. Relative expression of ASS1 was greater in APL than AML or GMPB. *P < .001. (E) Methylation of the ASS1 gene was assessed in 7 primary AML, 1 APL, and 1 GMPB samples. Six of 7 AML samples show some methylation, whereas the APL does not. U, unmethylated DNA; M methylated DNA. Farideh Miraki-Moud et al. Blood 2015;125:4060-4068 ©2015 by American Society of Hematology

Arginine is depleted in mice receiving ADI-PEG 20, and this leads to reduced AML burden. Arginine is depleted in mice receiving ADI-PEG 20, and this leads to reduced AML burden. (A) Plasma arginine was reduced in mice receiving ADI-PEG 20 either alone or in combination with cytarabine (data from 95 mice are shown). (B) Plasma citrulline levels were increased in mice receiving ADI-PEG 20 (data from 95 mice are shown). (C-H) The effects of ADI-PEG 20, cytarabine, and combination therapy on bone marrow AML percentage is shown. (C-E) ADI-PEG 20 alone reduced the percentage of AML in 3 experiments (AML samples 2, 3, and 5). (C-F) Cytarabine alone reduced the percentage of AML in 4 experiments (AML samples 2, 3, 4, and 5). (G-H) Neither drug alone was effective for AML samples 1 and 6, but the combination was effective in both. *P < .05. Farideh Miraki-Moud et al. Blood 2015;125:4060-4068 ©2015 by American Society of Hematology

ASS1-expressing normal hematopoietic cells are seen following suc-cessful AML clearance by ADI-PEG 20. ASS1-expressing normal hematopoietic cells are seen following suc-cessful AML clearance by ADI-PEG 20. Bone marrow sections from mice transplanted with AML sample 3 following treatment with vehicle or ADI-PEG 20 were stained with hematoxylin and eosin to assess residual hematopoiesis. The majority of cells in mice receiving vehicle were leukemic (A), whereas normal hematopoietic cells, including megakaryocytes (arrowed), are seen in mice treated with ADI-PEG 20 (B). ASS1 expression was lower in mice receiving vehicle (C) than mice receiving ADI-PEG 20 (D). Slides were analyzed using a Leica DM2500 microscope (magnification ×400 [A-B], ×200 [C-D]), and images were acquired by a Leica DFC320 camera and processed using Leica IM50 software. ASS1 was not expressed by AML cells (E) but was expressed by nonhuman marrow cells in mice treated with ADI-PEG 20 (F). Images were captured on an LSM510 Meta confocal laser microscope using a 40 × 1.3 oil immersion objective. Farideh Miraki-Moud et al. Blood 2015;125:4060-4068 ©2015 by American Society of Hematology

Apoptosis induction by ADI-PEG 20 in resistant and sensitive AML in vitro. Apoptosis induction by ADI-PEG 20 in resistant and sensitive AML in vitro. ADI-PEG 20 induced apoptosis in half the AML samples in vitro. The expression of active caspase 3/7 following ADI-PEG 20 administration is shown in the ADI-sensitive (n = 19) and ADI-resistant AMLs (n = 19) as well as GMPB (n = 9) and normal hematopoietic stem cells (HSCs; n = 4) (A). Similar data were observed for annexin-V expression (B) for ADI-PEG 20–sensitive (n = 13) and ADI-PEG 20–resistant AML (n = 10) and GMPB (n = 7). (C) Cell death as defined by 4,6-diamidino-2-phenylindole staining was increased in sensitive AMLs (n = 13) but not resistant AML (n = 10), GMPB (n = 7), or normal HSCs (n = 4). Numbers of viable AML cells were reduced in ADI-PEG 20–sensitive AMLs (n = 19) but not ADI-PEG 20–resistant AML (n = 19) nor GMPB (n = 9) (D). *P < .05 Farideh Miraki-Moud et al. Blood 2015;125:4060-4068 ©2015 by American Society of Hematology

Expression of ASS1 and ASL is higher in ADI-PEG 20–resistant AML and normal HSCs. The relative expression of ASS1 mRNA (A) and ASL mRNA (B) was significantly higher in ADI-PEG 20–resistant AML (n = 18) than in ADI-PEG 20–sensitive AML (n = 19). Expression of ASS1 and ASL is higher in ADI-PEG 20–resistant AML and normal HSCs. The relative expression of ASS1 mRNA (A) and ASL mRNA (B) was significantly higher in ADI-PEG 20–resistant AML (n = 18) than in ADI-PEG 20–sensitive AML (n = 19). ASS1 expression was higher in AML (n = 13) and GMPB (n = 4) after in vitro culture following ADI-PEG 20 exposure compared with control (C). Normal human bone marrow HSCs expressed greater amounts of ASS1 than lymphocytes or other marrow cells (CD34− CD3− CD19−) cells (n = 6) (D). (E) The uptake of labeled 13C6 arginine after 10 minutes was greater in sensitive AML (n = 6) than resistant AML (n = 6). The uptake of labeled arginine was significantly reduced by cationic amino acid transporter-1 (CAT-1) inhibitor in sensitive AML cells only. (F) Plasma arginine concentration was measured in patients at diagnosis of AML (n = 15). The arginine concentration was significantly lower than in healthy controls (n = 5). *P < .05. Farideh Miraki-Moud et al. Blood 2015;125:4060-4068 ©2015 by American Society of Hematology